Aileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924
Preliminary findings from ongoing Phase 1 healthy volunteer study will include data relating to mechanism
Preliminary findings from ongoing Phase 1 healthy volunteer study will include data relating to mechanism